JP2008523098A - ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 - Google Patents

ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 Download PDF

Info

Publication number
JP2008523098A
JP2008523098A JP2007545685A JP2007545685A JP2008523098A JP 2008523098 A JP2008523098 A JP 2008523098A JP 2007545685 A JP2007545685 A JP 2007545685A JP 2007545685 A JP2007545685 A JP 2007545685A JP 2008523098 A JP2008523098 A JP 2008523098A
Authority
JP
Japan
Prior art keywords
nucleoside
mmol
fluoro
cyclobutyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007545685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008523098A5 (enExample
Inventor
リオツタ，デニス・シー
マオ，シヨリ
ヘイガー，マイケル
Original Assignee
エモリー・ユニバーシテイ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エモリー・ユニバーシテイ filed Critical エモリー・ユニバーシテイ
Publication of JP2008523098A publication Critical patent/JP2008523098A/ja
Publication of JP2008523098A5 publication Critical patent/JP2008523098A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2007545685A 2004-12-10 2005-12-08 ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体 Withdrawn JP2008523098A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63487504P 2004-12-10 2004-12-10
PCT/US2005/044709 WO2006063281A2 (en) 2004-12-10 2005-12-08 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation

Publications (2)

Publication Number Publication Date
JP2008523098A true JP2008523098A (ja) 2008-07-03
JP2008523098A5 JP2008523098A5 (enExample) 2009-01-29

Family

ID=36578634

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007545685A Withdrawn JP2008523098A (ja) 2004-12-10 2005-12-08 ウィルス感染および異常細胞増殖の治療用の２′および３′−置換シクロブチルヌクレオシド類縁体

Country Status (9)

Country Link
US (2) US7495006B2 (enExample)
EP (1) EP1828145A4 (enExample)
JP (1) JP2008523098A (enExample)
CN (1) CN101115725A (enExample)
AU (1) AU2005313912A1 (enExample)
BR (1) BRPI0518984A2 (enExample)
CA (1) CA2590115A1 (enExample)
MX (1) MX2007006961A (enExample)
WO (1) WO2006063281A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781960B (zh) * 2016-10-03 2022-11-01 美商阿克思生物科學有限公司 腺核苷5'-核苷酸酶之抑制劑及相關用途

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8114414B2 (en) * 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US7794729B2 (en) * 1994-11-08 2010-09-14 The Trustees Of The University Of Pennsylvania Methods and compositions for immunotherapy of cancer
US8956621B2 (en) 1994-11-08 2015-02-17 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical dysplasia
US8791237B2 (en) * 1994-11-08 2014-07-29 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of non-hodgkins lymphoma
US7820180B2 (en) * 2004-09-24 2010-10-26 The Trustees Of The University Of Pennsylvania Listeria-based and LLO-based vaccines
US9012141B2 (en) * 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
EP1303299B1 (en) * 2000-03-29 2010-07-28 The Trustees of The University of Pennsylvania Use of prokaryotic pest-like peptides for enhancing immunogenicity of antigens
US8771702B2 (en) 2001-03-26 2014-07-08 The Trustees Of The University Of Pennsylvania Non-hemolytic LLO fusion proteins and methods of utilizing same
US7700344B2 (en) * 2001-03-26 2010-04-20 The Trustees Of The University Of Pennsylvania Compositions and methods for enhancing the immunogenicity of antigens
WO2006063281A2 (en) * 2004-12-10 2006-06-15 Emory University 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US8722686B2 (en) 2008-09-19 2014-05-13 Pfizer Inc. Hydroxamic acid derivatives useful as antibacterial agents
PL2512474T3 (pl) 2009-12-16 2015-03-31 Pfizer N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne
GEP20156370B (en) 2011-03-07 2015-09-25 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
EP2694488B1 (en) 2011-04-08 2014-11-12 Pfizer Inc Isoxazole derivatives useful as antibacterial agents
EP2694481B1 (en) 2011-04-08 2015-12-30 Pfizer Inc Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
US9708357B2 (en) 2011-12-20 2017-07-18 Riboscience, LLC 4′-azido, 3′-fluoro substituted nucleoside derivatives as inhibitors of HCV RNA replication
UA111761C2 (uk) 2011-12-20 2016-06-10 Рібосаєнс Ллс 2',4'-дифтор-2'-метилзаміщені нуклеозидні похідні як інгібітори реплікації phk вірусу гепатиту c
MA46490A1 (fr) 2013-05-16 2021-04-30 Riboscience Llc Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
HK1219901A1 (zh) 2013-05-16 2017-04-21 Riboscience Llc 4’-叠氮基，3’-脱氧基-3’-氟取代的核苷衍生物
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
WO2016079688A1 (en) 2014-11-19 2016-05-26 Actelion Pharmaceuticals Ltd Antibacterial benzothiazole derivatives
GEP20217282B (en) 2015-03-06 2021-08-10 Atea Pharmaceuticals Inc β-D-2'-DEOXY-2'α-FLUORO-2'-β-C-SUBSTITUTED-2-MODIFIED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR HCV TREATMENT
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
PT3512863T (pt) 2016-09-07 2022-03-09 Atea Pharmaceuticals Inc Nucleótidos de purina 2'-substituídos-n6-substituídos para tratamento de vírus de rna
CN110248951B (zh) 2017-02-01 2022-10-28 阿堤亚制药公司 用于治疗丙型肝炎病毒的核苷酸半硫酸盐
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2019200005A1 (en) 2018-04-10 2019-10-17 Atea Pharmaceuticals, Inc. Treatment of hcv infected patients with cirrhosis
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19
BR112023026356A2 (pt) 2021-06-17 2024-03-05 Atea Pharmaceuticals Inc Método para tratar vírus da hepatite c ou uma condição resultante de uma infecção por hepatite c, combinação, uso da combinação, composição farmacêutica, e, kit para o tratamento de vírus da hepatite c
CN119431343B (zh) * 2024-11-04 2026-04-10 河南大学 一种m6A去甲基化酶ALKBH1小分子抑制剂、合成方法及应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4855466A (en) * 1987-12-28 1989-08-08 E. R. Squibb & Sons, Inc. Purinyl cyclobutanes
EP0330992A3 (en) * 1988-02-29 1991-11-06 Nippon Kayaku Kabushiki Kaisha Novel cyclobutane derivatives, processes for their preparation and pharmaceutical compositions comprising them
US5126345A (en) * 1988-03-30 1992-06-30 E. R. Squibb & Sons, Inc. Bis (hydroxymethyl) cyclobutyl triazolopyrimidines
US5185459A (en) * 1988-03-30 1993-02-09 E. R. Squibb & Sons Inc. Bis protected (hydroxymethyl)cyclobutanols
US5130462A (en) * 1988-03-30 1992-07-14 E. R. Squibb & Sons, Inc. Cyclobutane derivatives
IL92096A0 (en) * 1988-10-25 1990-07-12 Abbott Lab Carboxylic nucleoside analogs
US4918075A (en) * 1988-12-20 1990-04-17 E. R. Squibb & Sons, Inc. Purinyl and pyrimidinyl cyclobutanes and their use as antiviral agents
AU635642B2 (en) * 1990-05-24 1993-03-25 E.R. Squibb & Sons, Inc. Fluorinated bis(hydroxymethyl) cyclobutyl purines and pyrimidines
US5324730A (en) * 1990-05-24 1994-06-28 Nippon Kayaku Kabushiki Kaisha Phenoxyphosphoryloxymethyl cyclobutyl purines
US5166397A (en) * 1990-09-20 1992-11-24 Nippon Kayaku Kabushiki Kaisha Process for producing optically active cyclobutylamines
US20040229839A1 (en) * 2003-05-14 2004-11-18 Biocryst Pharmaceuticals, Inc. Substituted nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases
WO2006063281A2 (en) 2004-12-10 2006-06-15 Emory University 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI781960B (zh) * 2016-10-03 2022-11-01 美商阿克思生物科學有限公司 腺核苷5'-核苷酸酶之抑制劑及相關用途

Also Published As

Publication number Publication date
EP1828145A2 (en) 2007-09-05
US20090149416A1 (en) 2009-06-11
BRPI0518984A2 (pt) 2008-12-16
WO2006063281A3 (en) 2006-10-12
AU2005313912A1 (en) 2006-06-15
US20060223835A1 (en) 2006-10-05
US7495006B2 (en) 2009-02-24
MX2007006961A (es) 2007-10-04
CN101115725A (zh) 2008-01-30
CA2590115A1 (en) 2006-06-15
US8114994B2 (en) 2012-02-14
EP1828145A4 (en) 2009-08-19
WO2006063281A2 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
US8114994B2 (en) 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation
US8895531B2 (en) 2′-fluoronucleoside phosphonates as antiviral agents
US9861652B2 (en) 2′ Fluoronucleosides
US6949522B2 (en) β-2′- or 3′-halonucleosides
US6245749B1 (en) Nucleosides with anti-hepatitis B virus activity
US20090274686A1 (en) Nucleoside phosphonate derivatives
JP2011246469A (ja) Ｂ型肝炎ウイルス活性を持ったヌクレオシド
CN1196701C (zh) 1,3－氧硒戊环核苷的合成及抗人类免疫缺陷病毒和抗乙肝病毒活性
JP2011251968A (ja) ＨＩＶ感染の治療のためのβ−Ｌ−２’−デオキシ−ヌクレオシド
CN101089010A (zh) 2＇－氟代核苷
EP1754710A2 (en) 2'-Fluoroncucleosides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081203

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20090702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090717